Critical role for IL-17A/F in the Immunopathogenesis of Obliterative airway disease induced by anti-mhc i antibodies

Transplantation

Volumn 95, Issue 2, 2013, Pages 293-300

  Basha, Haseeb Ilias ^a   Ramachandran, Sabarinathan ^a   Tiriveedhi, Venkataswarup ^a   Takenaka, Masashi ^a   Subramanian, Vijay ^a   Nath, Dilip S ^a   Benshoff, Nicholas ^a   Patterson, G Alec ^a   Mohanakumar, Thalachallour ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti MHC; Autoimmunity.; IL 17

Indexed keywords

ALLOANTIBODY; ALPHA TUBULIN; AUTOANTIBODY; CD11B ANTIGEN; COLLAGEN ANTIBODY; COLLAGEN TYPE 5; HLA ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17F; K ALPHA 1 TUBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CELLULAR SECRETION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; LUNG FIBROSIS; LUNG INFILTRATE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NONHUMAN; OBSTRUCTIVE AIRWAY DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; TH17 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD11B; AUTOANTIBODIES; AUTOIMMUNITY; BIOLOGICAL MARKERS; BRONCHIOLES; BRONCHIOLITIS OBLITERANS; COLLAGEN TYPE V; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; INFLAMMATION MEDIATORS; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION; TH17 CELLS; TIME FACTORS; TUBULIN;

EID: 84872898468     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182772244     Document Type: Article

References (32)

1. Lama VN, Murray S, Lonigro RJ, et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007; 175: 1192.
2. Hachem RR, Khalifah AP, Chakinala MM, et al. The significance of a single episode of minimal acute rejection after lung transplantation. Transplantation 2005; 80: 1406.
3. Jaramillo A, Smith MA, Phelan D, et al. Temporal relationship between the development of anti-HLA antibodies and the development of bronchiolitis obliterans syndrome after lung transplantation. Transplant Proc 1999; 31: 185.
4. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISAdetected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67: 1155.
5. Saini D, Weber J, Ramachandran S, et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J Heart Lung Transplant 2011; 30: 624.
6. Sato M, Keshavjee S. Bronchiolitis obliterans syndrome: alloimmunedependent and -independent injury with aberrant tissue remodeling. Semin Thoracic Cardiovasc Surg 2008; 20: 173.
7. Lu KC, Jaramillo A, Mendeloff EN, et al. Concomitant allorecognition of mismatched donor HLA class I- and class II-derived peptides in pediatric lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2003; 22: 35.
8. Sundaresan S, Mohanakumar T, Smith MA, et al. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65: 648.
9. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1129.
10. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007; 117: 3498.
11. Goers TA, Ramachandran S, Aloush A, et al. De novo production of K-alpha 1 tubulin-specific Abs: role in chronic lung allograft rejection. J Immunol 2008; 180: 4487.
12. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182: 309.
13. Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003; 14: 155.
14. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. Ann Rev Immunol 2009; 27: 485.
15. Zhang X, Angkasekwinai P, Dong C, et al. Structure and function of interleukin-17 family cytokines. Protein Cell 2011; 2: 26.
16. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001; 20: 5332.
17. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.
18. Nat Immunol 2005; 6: 1133.
19. Martinez GJ, Nurieva RI, Yang XO, et al. Regulation and function of proinflammatory TH17 cells. Ann N Y Acad Sci 2008; 1143: 188.
20. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205: 1063.
21. Jaramillo A, Fernandez FG, Kuo EY, et al. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant 2005; 9: 84.
22. Harris PE, Bian H, Reed EF. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 1997; 159: 5697.
23. Jaramillo A, Smith CR, Maruyama T, et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64: 521.
24. Bharat A, Fields RC, Trulock EP, et al. Induction of IL-10 suppressors in lung transplant patients by CD4+25+ regulatory T cells through CTLA-4 signaling. J Immunol 2006; 177: 5631.
25. Hachem RR. Lung allograft rejection: diagnosis and management. Curr Opin Organ Transplant 2009; 14: 477.
26. Hu Y, Ota N, Peng I, et al. IL-17RC is required for IL-17A- and IL- 17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 2010; 184: 4307.
27. Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol 2007; 179: 7128.
28. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukocyte Biol 2002; 71: 1.
29. Bharat A, Fields RC, Mohanakumar T. Regulatory T cell-mediated transplantation tolerance. Immunol Res 2005; 33: 195.
30. Bharat A, Fields RC, Steward N, et al. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 2006; 6: 1799.
31. Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 2008; 181: 2799.
32. Hsu HC, Yang P, Wang J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008; 9: 166.